TITLE

A validated spectrofluorometric method for the determination of celecoxib in capsules

AUTHOR(S)
Damiani, Patricia; Bearzotti, Mariela; Cabezón, Miguel A.
PUB. DATE
August 2003
SOURCE
Analytical & Bioanalytical Chemistry;Aug2003, Vol. 376 Issue 7, p1141
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A rapid, selective, sensitive and simple fluorescence method was developed for the direct determination of celecoxib in capsules. The capsules were emptied, pulverized and dissolved in either ethanol or acetonitrile, sonicated and filtered. Direct fluorescence emission was measured at 355±5 nm (exciting at 272 nm). The method was fully validated and the recoveries were excellent, even in presence of excipients.
ACCESSION #
15124662

 

Related Articles

  • celecoxib.  // Royal Society of Medicine: Medicines;2002, p146 

    The article presents information on Celecoxib, a non-narcotic analgesic and antirheumatic drug which is used to treat the pain and inflammation of osteoarthritis and rheumatoid arthritis. Administration of the drug is oral. Side effects of the drug are flatulence, insomnia, inflammation of the...

  • APC trial stopped: increased risk of cardiovascular events with celecoxib.  // Reactions Weekly;1/8/2005, Issue 1033, p2 

    Reports that the U.S. National Cancer Institute Data Safety and Monitoring Board has stopped drug administration in the Adenoma Prevention with Celecoxib (APC). Result of the APC study; Other celecoxib trails that has also been evaluated in the U.S.; Effects of the use of celecoxib on patients.

  • Formulation, Evaluation and Optimization of Orally Disintegrating Tablet of Piroxicam. Prajapati, Bhupendra G.; Patel, Bhaskar // International Journal of PharmTech Research;Jul-Sep2010, Vol. 2 Issue 3, p1893 

    Objective of this study was to formulate directly compressible orally disintegrating tablets of piroxicam with sufficient mechanical integrity, content uniformity, and acceptable palatability to assist patients of any age group for easy administration. Effect of varying concentrations of...

  • Regulations for COX-2 inhibitors.  // WHO Drug Information;2004, Vol. 18 Issue 4, p283 

    Reports on the withdrawal of the manufacturer of Celecoxib from the Turkish market after the Turkish Ministry of Health asked for a new warnings to be added to the package as decided by the Human Medicinal Products Advisory Committee of the European Union in Turkey. List of the warnings to be...

  • health perspective. Vanderhaeghe, Lorna // Alive: Canada's Natural Health & Wellness Magazine;Sep2003, Issue 251, p8 

    Reports on the research at the University of Pennsylvania Medical Center, which found that Celebrex may also increase risk of heart attack and stroke. Dangerous side effects of Celebrex; Description of four cases of liver toxicity that is associated with kava-containing products.

  • Adverse Reaction Case Reports.  // Reactions Weekly;4/10/2004, Issue 996/997, p6 

    Describes several case reports on the side effects of various drugs. Occurrence of uveities following ophthalmic administration of bimatropost in an elderly patient; Details of a case of a possible interaction between itraconazole and inhaled budesonide resulted in Cushing's syndrome in a...

  • More symptomatic upper GI events with rofecoxib than celecoxib.  // Reactions Weekly;10/8/2005, Issue 1072, p5 

    Discusses research being done on gastrointestinal and thromboembolic events caused by refecoxib and celecoxib administration. Reference to a study by R. Kasliwal, D. Layton et al, published in the November 9, 2005 issue of the "Drug Safety"; Role of rofecoxib in the occurrence of symptomatic...

  • Celecoxib.  // Reactions Weekly;4/24/2004, Issue 998, p10 

    Presents information on a study by B. Milpied and colleagues on sever cutaneous drug reactions to celecoxib, published in the November 2003 issue of the "Annales de Dermatologie et de Venereologie" journal.

  • Celecoxib.  // Reactions Weekly;4/9/2005, Issue 1046, p9 

    Presents a case report on acute generalized exanthematous pustulosis caused by celecoxib. Description of exanthematous pustulosis; Information on the treatment of the disease; Association between drug intake and onset of skin eruption.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics